Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Perfetti

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
World Journal of Surgical Oncology|September 20, 2011
A metachronous splenic metastases from esophageal cancer: a case reportIvan Botrugno, Vassili Jemos, Lorenzo Cobianchi, et al.
Blood|April 9, 2004
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationGiovanni Palladini, Vittorio Perfetti, Laura Obici, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosisEfstathios Kastritis, Ashutosh D Wechalekar, Meletios A Dimopoulos, et al.
Blood|November 10, 2011
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44Vittorio Perfetti, Giovanni Palladini, Simona Casarini, et al.
Haematologica|December 6, 2006
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosisVittorio Perfetti, Salvatore Siena, Giovanni Palladini, et al.
Therapeutic Drug Monitoring|November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsMario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Endocrine Pathology|May 11, 2020
Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite ShiftAlessandro Vanoli, Vittorio Perfetti, Daniela Furlan, et al.
Annals of Hematology|September 10, 2008
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomideGiovanni Palladini, Paola Russo, Francesca Lavatelli, et al.
Biochimica Et Biophysica Acta|January 11, 2011
A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serumFrancesca Lavatelli, Francesca Brambilla, Veronica Valentini, et al.
Molecular Immunology|October 24, 2007
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulinsValentina Navazza, Silvia Gabba, Andrea Alfieri, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
World Journal of Surgical Oncology|September 20, 2011
A metachronous splenic metastases from esophageal cancer: a case reportIvan Botrugno, Vassili Jemos, Lorenzo Cobianchi, et al.
Blood|April 9, 2004
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationGiovanni Palladini, Vittorio Perfetti, Laura Obici, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosisEfstathios Kastritis, Ashutosh D Wechalekar, Meletios A Dimopoulos, et al.
Blood|November 10, 2011
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44Vittorio Perfetti, Giovanni Palladini, Simona Casarini, et al.
Haematologica|December 6, 2006
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosisVittorio Perfetti, Salvatore Siena, Giovanni Palladini, et al.
Therapeutic Drug Monitoring|November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsMario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Endocrine Pathology|May 11, 2020
Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite ShiftAlessandro Vanoli, Vittorio Perfetti, Daniela Furlan, et al.
Annals of Hematology|September 10, 2008
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomideGiovanni Palladini, Paola Russo, Francesca Lavatelli, et al.
Biochimica Et Biophysica Acta|January 11, 2011
A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serumFrancesca Lavatelli, Francesca Brambilla, Veronica Valentini, et al.
Molecular Immunology|October 24, 2007
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulinsValentina Navazza, Silvia Gabba, Andrea Alfieri, et al.
Pageof 6